Trial Profile
Phase 1 Study of IMC-1121B in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 19 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Dec 2010 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 15 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.